About Scilex Holding
Scilex Holding is a publicly listed company based in Palo Alto (United States) founded in 2019. Non-opioid therapies for acute and chronic pain are developed. The company has 115 employees. Scilex Holding has completed 1 acquisition, including Ancora Medical. Its chief executive, as recorded, is Jaisim Shah. Scilex Holding offers products and services including ZTLido, Elyxyb, and Gloperba. Its focus areas include Life Sciences, Pain Management, Drugs and Diversified. Its legal entity is Scilex Holding Company. Its competitors include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Developer of non-opioid therapies for acute and chronic pain. It offers a lead product Tlido a lidocaine topical product for post-shingles nerve pain. It also has other candidates SP-102 to treat lumbosacral radicular pain, SP-103 for the treatment of low back pain, and SP-104 for chronic pain and fibromyalgia.
- Headquarters Palo Alto, United States
- Employees 115
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website scilexholding.com
- Social LinkedIn Facebook
- Legal Name Scilex Holding Company
- Annual Revenue$30.25 M (USD)-46.54as on Dec 31, 2025
- Net Profit-$402.49 M (USD)-452.81as on Dec 31, 2025
- EBITDA-$267.68 M (USD)-201.64as on Dec 31, 2025
- Employee Count115
- Investments & Acquisitions
Products & Services of Scilex Holding
Scilex Holding offers a comprehensive portfolio of products and services, including ZTLido, Elyxyb, and Gloperba.
Optimizes drug delivery for chronic pain through proprietary adhesion.
Provides fast relief for migraines with individualized dosing options.
Offers precision dosing as the first liquid gout medicine available.
People of Scilex Holding
1 people are tracked at Scilex Holding (1 in leadership); the tracked headcount is 115.
| Name | Role | Group |
|---|---|---|
Jaisim Shah | CEO | Leadership |
Complete people profiles for Scilex Holding
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Scilex Holding
Scilex Holding is a publicly listed company on the NASDAQ with ticker symbol SCLX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Nov 2022
- Listed onNASDAQ: SCLX
- Listed entityScilex Holding Company
- Exchange sectorHealth technology
- ISINUS80880W2052
- Share price$2.88 (+2.86% on the day) · 2026-10-13
- Market capitalisation$20.3M
- EPS (diluted, trailing year)$-49.80
- Volume (last session)33,973
Financials of Scilex Holding
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $30.2M | -$402.5M | -$267.7M |
| 2024 | $56.6M | -$72.8M | -$88.7M |
| 2023 | $46.7M | -$114.3M | -$101.3M |
| 2022 | $38.0M | -$23.4M | -$46.2M |
| 2021 | $31.3M | -$88.4M | -$31.7M |
Detailed financial statements for Scilex Holding
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Scilex Holding
Scilex Holding has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Ancora Medical.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of a surgical pain management device | ancoramedical.tcc.mode | Menlo Park, United States | 2020 | Jul 2022 | •••• |
Complete acquisition details for Scilex Holding
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Scilex Holding
3 dated milestones of Scilex Holding across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Scilex Holding is founded.
- Acquisition Acquires Ancora Medical.
- IPO Lists on the stock exchange (IPO).
Competitors of Scilex Holding
Scilex Holding has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| caratherapeutics.com | 2004 | New York, United States | $51M | 79 | Developer of therapeutics for pain relief and inflammatory diseases | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. |
Detailed competitors of Scilex Holding
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Scilex Holding
The website of Scilex Holding (scilexholding.com) receives about 5.8K visits a month.
- Monthly visits5.8K
▲ 15.7% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Scilex Holding (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Scilex Holding
Complete news archive for Scilex Holding
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scilex Holding
Scilex Holding was founded in 2019.
Scilex Holding is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Jaisim Shah is the CEO of Scilex Holding, as recorded in our data.
Scilex Holding has 115 employees.
Annual revenue of Scilex Holding is $30.25M as on Dec 31, 2025.
Developer of non-opioid therapies for acute and chronic pain. It offers a lead product Tlido a lidocaine topical product for post-shingles nerve pain. It also has other candidates SP-102 to treat lumbosacral radicular pain, SP-103 for the treatment of low back pain, and SP-104 for chronic pain and fibromyalgia.
Scilex Holding's top competitors include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics.
Scilex Holding offers ZTLido, Elyxyb, and Gloperba.
Yes, Scilex Holding is publicly traded on NASDAQ under the ticker symbol SCLX.
Scilex Holding has made 1 acquisition, including Ancora Medical.
Scilex Holding operates through Scilex Holding Company.